KR20180032578A - 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도 - Google Patents

염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도 Download PDF

Info

Publication number
KR20180032578A
KR20180032578A KR1020187002620A KR20187002620A KR20180032578A KR 20180032578 A KR20180032578 A KR 20180032578A KR 1020187002620 A KR1020187002620 A KR 1020187002620A KR 20187002620 A KR20187002620 A KR 20187002620A KR 20180032578 A KR20180032578 A KR 20180032578A
Authority
KR
South Korea
Prior art keywords
subject
effective amount
administration
dose
chloroquine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187002620A
Other languages
English (en)
Korean (ko)
Inventor
제프리 에스. 글렌
에드워드 에이. 팜
Original Assignee
아이거 그룹 인터내셔널, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이거 그룹 인터내셔널, 인코포레이티드 filed Critical 아이거 그룹 인터내셔널, 인코포레이티드
Priority to KR1020237028986A priority Critical patent/KR20230129590A/ko
Publication of KR20180032578A publication Critical patent/KR20180032578A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187002620A 2015-06-30 2016-06-30 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도 Ceased KR20180032578A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237028986A KR20230129590A (ko) 2015-06-30 2016-06-30 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
US62/187,061 2015-06-30
PCT/US2016/040566 WO2017004454A1 (en) 2015-06-30 2016-06-30 Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028986A Division KR20230129590A (ko) 2015-06-30 2016-06-30 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도

Publications (1)

Publication Number Publication Date
KR20180032578A true KR20180032578A (ko) 2018-03-30

Family

ID=57609247

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187002620A Ceased KR20180032578A (ko) 2015-06-30 2016-06-30 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도
KR1020237028986A Ceased KR20230129590A (ko) 2015-06-30 2016-06-30 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237028986A Ceased KR20230129590A (ko) 2015-06-30 2016-06-30 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도

Country Status (14)

Country Link
US (3) US10688083B2 (https=)
EP (1) EP3317274A4 (https=)
JP (3) JP7068827B2 (https=)
KR (2) KR20180032578A (https=)
CN (2) CN107922404B (https=)
AU (4) AU2016288699B2 (https=)
CA (3) CA3178499A1 (https=)
HK (1) HK1249508A1 (https=)
IL (4) IL310969A (https=)
MX (3) MX394605B (https=)
NZ (1) NZ776616A (https=)
TW (3) TWI771272B (https=)
WO (1) WO2017004454A1 (https=)
ZA (2) ZA201708471B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178499A1 (en) * 2015-06-30 2017-01-05 Eiger Group International, Inc. Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
US12372530B2 (en) * 2017-11-15 2025-07-29 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) * 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
JP2002543122A (ja) * 1999-04-30 2002-12-17 エイピーティー ファーマスーティカルズ エルエルスィー 抗マラリア治療剤についての新規使用
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
JP2006517969A (ja) 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP1656124A1 (en) * 2003-03-12 2006-05-17 Cerenis Methods and compositions for the treatment of cancer
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
CA2543696A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) * 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
ES2462541T3 (es) * 2005-06-09 2014-05-23 Meda Ab Método y composición para el tratamiento de trastornos inflamatorios
EP1981524A2 (en) 2006-02-09 2008-10-22 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
EP2203168B1 (en) * 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US20100285001A1 (en) * 2007-10-02 2010-11-11 University Of Rochester Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
ES2738101T3 (es) * 2009-07-31 2020-01-20 Smc Global Asset Inc Ratón modelo de esteatohepatitis-cáncer de hígado
CA3104704A1 (en) * 2009-08-14 2011-02-17 Revivicor, Inc. Multi-transgenic pigs for diabetes treatment
WO2011041311A2 (en) * 2009-09-29 2011-04-07 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
EP2488180A4 (en) * 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON-ALCOHOLIC FAT TREATMENTS
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
WO2013125543A1 (ja) * 2012-02-20 2013-08-29 武田薬品工業株式会社 複素環化合物
US20130273003A1 (en) * 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2013180149A1 (ja) 2012-05-30 2013-12-05 富山化学工業株式会社 重水素化含窒素複素環カルボキサミド誘導体またはその塩
WO2014031769A2 (en) * 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
RU2016125213A (ru) * 2013-11-27 2017-12-29 АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Нуклеотиды для лечения рака печени
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CA3178499A1 (en) * 2015-06-30 2017-01-05 Eiger Group International, Inc. Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition

Also Published As

Publication number Publication date
IL279020B1 (en) 2023-03-01
EP3317274A4 (en) 2019-05-08
IL279020B2 (en) 2023-07-01
CN113274386A (zh) 2021-08-20
TW202317103A (zh) 2023-05-01
CN107922404A (zh) 2018-04-17
AU2024266943A1 (en) 2024-12-19
BR112017028601A2 (pt) 2018-08-28
NZ738291A (en) 2021-06-25
KR20230129590A (ko) 2023-09-08
TWI830262B (zh) 2024-01-21
IL300476A (en) 2023-04-01
US20240398761A1 (en) 2024-12-05
US10688083B2 (en) 2020-06-23
MX2017016681A (es) 2018-07-06
IL310969A (en) 2024-04-01
WO2017004454A8 (en) 2018-01-25
JP2018519340A (ja) 2018-07-19
AU2023201397A1 (en) 2023-04-06
JP7470151B2 (ja) 2024-04-17
US20180200228A1 (en) 2018-07-19
IL300476B2 (en) 2024-07-01
IL279020A (https=) 2020-12-31
TWI881480B (zh) 2025-04-21
ZA201708471B (en) 2022-05-25
JP7068827B2 (ja) 2022-05-17
US12090141B2 (en) 2024-09-17
CA2989634A1 (en) 2017-01-05
CA3294570A1 (en) 2026-03-02
AU2021201234A1 (en) 2021-03-11
IL300476B1 (en) 2024-03-01
TW201717941A (zh) 2017-06-01
NZ776616A (en) 2024-11-29
CN107922404B (zh) 2021-06-29
ZA202004136B (en) 2025-08-27
JP2022105149A (ja) 2022-07-12
AU2023201397B2 (en) 2024-10-03
TW202402283A (zh) 2024-01-16
US20210052553A1 (en) 2021-02-25
JP7810746B2 (ja) 2026-02-03
MX2022008100A (es) 2022-07-11
MX394605B (es) 2025-03-24
HK1249508A1 (zh) 2018-11-02
JP2024083475A (ja) 2024-06-21
WO2017004454A1 (en) 2017-01-05
IL256233A (en) 2018-02-28
CA2989634C (en) 2022-12-06
EP3317274A1 (en) 2018-05-09
MX2023003792A (es) 2023-04-26
CA3178499A1 (en) 2017-01-05
AU2016288699B2 (en) 2020-11-26
TWI771272B (zh) 2022-07-21
AU2016288699A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
US20240398761A1 (en) Use of Chloroquine Compounds for Treatment of Inflammatory Conditions
KR102011641B1 (ko) 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
EP3458448B1 (en) Fasn inhibitors for use in treating non-alcoholic steatohepatitis
JP6386590B2 (ja) Ａｍｐ依存性プロテインキナーゼを活性化するための医薬を製造するためのイソキノリンアルカロイド誘導体の使用
US20180022734A1 (en) Sunitinib prodrug and pharmaceutical composition
NZ738291B2 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
KR20220107036A (ko) 좌선성 바이사이클릭 모르폴린 및 그의 염, 그의 제조 방법, 약제학적 조성물, 및 용도
KR20130100574A (ko) 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 다약제 내성 억제용 약학적 조성물
BR112017028601B1 (pt) Uso de clemizol
JP2004292366A (ja) １，２−ジオキサン化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190708

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200908

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200908

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210305

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190708

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211129

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220622

Patent event code: PE09021S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230426

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220622

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220128

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211129

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20211020

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210720

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210305

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200908

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190708

X601 Decision of rejection after re-examination